Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from TuHURA Biosciences ( (HURA) ) is now available.
In June 2025, TuHURA Biosciences initiated a Phase 3 trial for its lead product, IFx-2.0, as an adjunctive therapy to Keytruda in treating advanced Merkel cell carcinoma, aiming for accelerated FDA approval. Following its acquisition of Kineta, TuHURA plans a Phase 2 trial for TBS-2025, a VISTA-inhibiting antibody, in combination with a menin inhibitor for treating acute myeloid leukemia, potentially enhancing response rates and reducing relapse.
The most recent analyst rating on (HURA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
Spark’s Take on HURA Stock
According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.
TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.
To see Spark’s full report on HURA stock, click here.
More about TuHURA Biosciences
TuHURA Biosciences, Inc. is a clinical stage immuno-oncology company focused on developing novel therapeutics to overcome resistance to cancer immunotherapies. The company leverages its proprietary Immune FxTM technology platform, VISTA-inhibiting monoclonal antibodies, and Delta Opioid Receptor technology to create innovative treatments targeting tumor microenvironments and immune system modulation.
Average Trading Volume: 393,197
Technical Sentiment Signal: Strong Sell
Current Market Cap: $130.3M
See more data about HURA stock on TipRanks’ Stock Analysis page.